SUMMARY Inactive renln was partially purified from 4.5 liters of human plasma (502-fold, specific activity 0.8 X 10-' Goldblatt units/mg protein) and from 207 g renal cortex (103-fold, 52 X 10-* Goldblatt units/mg). In contrast to active renln, inactive renln from each source bound to Cibacron blue-agarose and was unable to bind to pepstatin-Sepbarose. Both plasma and renal inactive renln had weaker affinity for anion-exchange resins than the active form, both bound to concanavalin A-Sepharose and were eluted with carbohydrate, and both bound tightly to hydrophobic gels. Each substance could be isolated in a completely inactive form during small-scale pilot studies, but "spontaneous" activation did occur, to a limited degree, during large-scale purification; this was possibly due to a plasma serine protease that fractionated with inactive renin during the initial purification steps. Both plasma and renal inactive renln were activated irreversibly by trypsin. Following activation, each substance lost its ability to bind to Cibacron blue-agarose. Each could be activated fully by acidification at 4°C, but this activation was reversed during subsequent incubation at higher temperature and pH. There was no evidence of add protease activity in either preparation. Activated inactive renin from both plasma and kidney were identical to partially-purified active renal renin in terms of pH optimum (pH 5.5-6.0) and reaction kinetics (K m 0.8-1 J /iM) with homologous angiotensinogen, noncompetetive inhibition by pepstatin (K, 2.5-3.5 pM), and an identical inhibition profile by monospeciflc anrireoin antibodies. These results suggest that inactive renin from plasma and kidney may be the same substance and that their activated forms are similar to the endogenous!)' produced active enzyme, consistent with the possibility that inactive renin is a precursor of circulating active renin. A COMPLETELY inactive form of renin accounts for more than half of the total renin in normal human plasma.
At least two types of large molecular weight renins have been isolated from kidney extracts. A 55-60,000 dalton enzymatically active form, identified in several species, appears to represent a complex of 40,000-dalton renin with a cortical binding substance 10 "" and may be the predominant form of renin extracted under certain conditions, notably in the presence of sodium tetrathionate. 13 ' 1S Acidification 11 or treatment with reducing agents 1 * causes dissociation of the complex and, hence, reduction in molecular size; however, enzymatic activity is only modestly increased. In contrast, a completely inactive large molecular weight renin has been isolated recently from human and hog kidney.*' 14 " u This form constitutes about 10% to 30% of the total extracted renin and is quite similar to human plasma inactive renin in terms of certain chromatographic properties. A similar substance is present in perfusate of human kidney, 1 * suggesting that the kidney is a source of circulating inactive renin.
Despite their similarities, inactive renin from plasma appears to be somewhat larger (56,000 dal-RENAL AND PLASMA INACTIVE REWNS/Atlas et al. tons) than that from kidney (50,000 daltons).' However, active renin from plasma may also behave as a larger molecule than its renal counterpart.* 1 " Thus, differences in gel filtration behavior between renal and plasma renins might reflect differences in conformation or in the extent of glycosylation and not necessarily indicate a difference in primary structure. In the present report, we present additional biochemical evidence supporting the view that the inactive renins from human plasma and kidney may be the same substance.
Materials and Methods

Purified Reagents
Active renin (specific activity, 0.08 Goldblatt units (GU)/mg protein) was partially purified from human kidneys by the method of Haas et al. 1 ' Angiotensinogen (specific activity, 3.5 nmoles/mg) was purified from human plasma. 1 '
Enzymatic Assays
Renin Activity Renin activity was measured as the rate of angiotensin I (Al) formation from purified angiotensinogen at pH 5.7, 37°C, in the presence of 3 mM EDTA and 3 mM phenylmethylsulfonylfluoride;'1 "• *° it was expressed as ng or jtg Al/hr. The assay, standardized with Haas renin, was performed at 1.2 ^M angiotensinogen (142 ng AI/hr/GU) for plasma purification and at 0.5 fiM (90 jtg AI/hr/GU) in all other studies.
Inactive Renin
Inactive renin was determined as the increment in activity following activation with bovine pancreatic trypsin (Boehringer-Mannheim). Whole plasma was incubated for 1 hour at -4°C with 1.0 mg/ml trypsin; 81 chromatographic fractions and purified preparations were incubated for 1 hour at 25°C with 100 Mg/ml trypsin in the presence of 10 mM benzamidine-HCl and 0.5% bovine serum albumin."
Acid Protease Activity
Acid protease activity was determined at pH 3.2 by modification of the method of Anson" using [methylu C]-methylated-methemoglobin (New England Nuclear, 17.5 ^Ci/mg) as substrate.
TAME (L-Tosyl Arginine Methyl Ester) Esterase
Activity TAME esterase activity was measured using 'H-TAME (Biochemical and Nuclear Corporation, 200 mCi/mmole) as substrate.
2 * 1 " Activity, standardized with pure urinary kallikrein," was expressed as esterase units (EU)/ml.
Protein
Protein was measured by the method of Lowry et al."
Purification of Inactive Renin Plasma
Blood from normal human volunteers was collected in plastic bottles containing hexadimethrine (3 mM final concentration) and benzamidine (10 mM). These conditions were used to prevent surface-dependent activation of Hageman factor and any consequent proteolytic activity. Plasma (4.5 liters) was desalted on a 10 X 80 cm column of Sephadex G-25 (Pharmacia) equilibrated with Buffer A.* The proteincontaining eluates (void volume) were applied directly onto a 10 X 80 cm column of QAE-Sephadex A-50 (Pharmacia) equilibrated with the same buffer. The column was washed with 20 liters each of Buffer A containing 0, 0.12, 0.25, and then 0.35 M NaCl; 4-liter fractions were collected.
Inactive renin eluted between 0.05-0.12 M NaCl (fractions 2-5, peak fraction 3) whereas active renin eluted slightly later (fractions 3-7, peak fraction 4). Fractions 2-4 were pooled (12.2 liters), diluted with buffer to 0.10 M Na + , and divided into four portions, each of which was pumped at 3.0 ml/min onto a 5 X 80 cm column of blue-dextran-Sepharose 4B 1B equilibrated with Buffer B containing 0.10 M NaCl. The nonretained protein fraction was directly applied to a 5 X 90 cm column of Cibacron blue-F3G-Aagarose (Affi-Gel Blue, Bio-Rad) equilibrated with the same buffer. Since both gels bind albumin but only the later binds inactive renin, the capacity of Cibacron blue-agarose for inactive renin was increased nearly twofold by this procedure. The columns were washed in tandem with the starting buffer until all the protein had passed onto the second column. The Cibacron blue-agarose column was then washed separately with 8 to 10 liters of starting buffer; inactive renin was then eluted with 5 liters of Buffer B containing 1.0 M NaCl. The protein-containing eluates were pooled, concentrated (Amicon, PM-10 membrane), and dialyzed three times against 20 vol Buffer C containing 30 mM NaCl. This material was divided into three portions, which were applied separately at 3.0 ml/min to a 4 X 45 cm column of CM-cellulose (CM-52, Whatman) equilibrated with Buffer C. After washing with 1500 ml buffer, the retained proteins were eluted with a linear gradient of NaCl (30 to 240 mM) in Buffer C (total vol, 6 liters). Inactive renin-containing fractions from each run were pooled, concentrated to about 5 ml, dialyzed twice against 100 vol Buffer D, and applied to a 2.6 X 95 cm column of Sephadex G-150 (Pharmacia) equilibrated with the latter buffer. Flow rate was 0.4 ml/min and 15-minute fractions were collected.
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Renal Inactive Renin
Cortex (207 g), dissected from previously frozen cadaver kidneys, was minced and homogenized as previously described 9 in 414 ml Buffer B containing 0.1 M NaCl; di-isopyropylfiuorophosphate (5 mM final concentration) was added after the first homogenization. The homogenate was centrifuged (4°C) at 10,000 X g for 20 minutes (Sorvall centrifuge, GSA head), and the pellet was rehomogenized in 207 ml buffer. The combined supernatants were centrifuged at 19,000 X g for 60 minutes. This supernatant was applied to a 5 X 90 cm column of Cibacron blueagarose, equilibrated with the homogenization buffer, at 3.8 ml/min. The column was washed with 8 liters of starting buffer followed by 4 liters of Buffer B containing 1.0 M NaCl. The elution of protein, active and inactive renin was identical to that described previously-" except that the residual particulate matter in the 19,000 X g supernatant eluted in the void volume, just ahead of the active renin peak. The inactive renin-containing fractions were pooled (Na = 0.7 M), adjusted to 1.0 M NaCl, and divided into three portions, each of which was applied to a 2.5 X 23 cm column of phenyl-Sepharose CL-4B (Pharmacia), equilibrated with Buffer B containing 1.0 M NaCl. The column was washed with 485 ml of starting buffer followed by a linear gradient (total volume 800 ml) of simultaneously decreasing NaCl (1.0 to 0 M) and increasing ethylene glycol (0 to 50%) in Buffer B. The inactive renin-containing fractions from each run were pooled, concentrated, dialyzed three times against Buffer E, and then applied to a 0.9 X 24 cm column of DEAE-Sepharose CL-6B (Pharmacia) equilibrated with Buffer E. The column was washed with 64 ml of starting buffer followed by a NaCl gradient (0 to 100 mM) in Buffer E (total volume, 100 ml). The fractions containing inactive renin were pooled and concentrated.
Kinetic Studies and Pepstatin Inhibition
Preparations of active renal renin or trypsin-activated inactive renin were diluted 50-to 18,000-fold in Buffer F to approximately 1-2 X 10^ GU/ml, which provided a linear rate of AI generation for up to 1 hour and consumed less than 4% of the substrate at each concentration tested. Samples were incubated in duplicate with eight concentrations of angiotensinogen (range 0.13 to 2.6 nM), which provided an even distribution of reciprocal values. Data were examined by both Lineweaver-Burk and Eadie-Hofstee analyses 27 and regression lines determined by the method of least squares. Pepstatin A (Peninsula Laboratories) was dissolved and serially diluted in methanol. To determine the concentration producing 50% inhibition (ID M ) or the Ki by Dixon analysis," enzyme was preincubated in Buffer F with pepstatin (10"' to 10"' M) for 15 minutes at 25°C; angiotensinogen (0.4 or 0.8 nM) was then added and the samples incubated at 37°C. Michaelis-Menten analysis was performed as described above (eight substrate concentrations with and without pepstatin).
Antibody Inhibition
Rabbit antiserum to pure human renin, 1 *' M serially diluted in Buffer F, was preincubated with diluted enzyme for 1 hour at 37°C; angiotensinogen (0.5 /tM) was then added to determine renin activity. Preincubation of enzyme at 37°C without antiserum (for controls) did not affect activity.
Other Studies
The pH optimum of enzyme activity was determined using acetate, phosphate, and Tris buffers in the pH 4-8 range. 9 Methods for estimating molecular weight by gel filtration (Sephadex G-100; 2 X 96 cm) and for chromatography on pepstatin-aminohexylSepharose are described elsewhere.*
Results
Purification of Inactive Renlns Plasma Inactive Renin
Partial separation of active and inactive renin was achieved on QAE-Sephadex (table 1, Step 2), and separation was nearly complete after chromatography on Cibacron blue-agarose (Step 3). However, "spontaneous" activation of the inactive renin appeared to occur in subsequent steps. Active renin increased sixfold after concentration of the pooled fractions from Cibacron blue-agarose (Step 3a). In addition, when samples were dialyzed (24 hrs at 4°C) against pH 8.0 buffer to remove benzamidine, considerable activation occurred (10%-15% for Steps 2 and 3; 42%-47% for Step 3a). It was found that the Step 3a material had considerable TAME esterase activity (0.2 EU/mg protein), which might have caused activation. After chromatography on CM-cellulose (Step 4), a broad peak of TAME esterase activity was nearly completely separated from inactive renin ( fig. 1) , and subsequently the degree of activation during removal of benzamidine was markedly reduced, though not eliminated entirely (2%-5%). The Step 5 preparation has been stable at -40°C for nearly 2 years, although the percent active renin has gradually increased from 8% to 15%. For analytical studies, the residual active renin was removed by applying small aliquots to pepstatin-Sepharose or Cibacron blue-agarose.
Renal Inactive Renin
The majority of active renin was separated from inactive renin on Cibacron blue-agarose (Step 2), but, compared to earlier small-scale studies,*' ie a greater amount of active renin (19% of the total) was bound and coeluted with inactive renin during large-scale chromatography (table 2) . Both the residual active renin and inactive renin were tightly bound by phenylSepharose ( fig. 2 A) , indicating a strong hydrophobic character. In pilot experiments, inactive renin was not eluted by step-wise elimination of NaCl but was eluted by 50% ethylene glycol; however, the extent of purification was improved by a simultaneous gradient of decreasing NaCl and increasing ethylene glycol (fig. 2 Total renin activity (ng Al/hr) following trypsin activation; activity measured at 0.5 jiM angiotensinogen. fl GU = 90 Mg Al/hr. 
FIGURE 3. Chromatography of partially-purified renal inactive renin on Cibacron blue-F3G-A-agarose before (upper panel) and after (lower panel) trypsin activation. Untreated and activated aliquots of the step 4 material (table 2) were applied to a 2.5 X 20 cm column of gel equilibrated with Buffer B containing 0.1 M NaCl. The retained inactive renin (upper panel) was eluted with buffer containing 1.0 M NaCl (arrow). Following trypsin treatment, the activated inactive renin was no longer retained by the gel (lower panel).
A). Inactive renin may be even more hydrophobic than active renin. When an aliquot of Step 2 material was applied to octyl-Sepharose CL-4B, only the residual active renin could be eluted with ethylene glycol (70% recovery); the inactive renin was not recovered, even with non-ionic detergents. The residual active renin from the phenylSepharose step was separated from inactive renin on DEAE-Sepharose (Step 4); under the conditions used, the active renin was more firmly bound ( fig. 2 B) . This preparation has been stable at -40° C for over 8 months, although, like the plasma preparation, there has been a tendency for active renin to increase slightly (from 1% to 3%) with time.
Other Chromatographlc Properties of Inactive Renin
Partially-purified inactive renin from either plasma or kidney was bound by Cibacron blue-agarose. Following trypsin-activation, the ability to bind was lost ( fig. 3 ). Like renal inactive renin, partially purified inactive renin from plasma was firmly bound by phenyl-Sepharose. Both substances failed to bind to pepstatin-Sepharose in the inactive state. Both were bound by concanavalin A-Sepharose and could be Pre-incubation at 37 C C, pH 8 (mm) eluted with a-methyl-mannoside, suggesting that they are glycoproteins.
FIGURE 4. Reversible acid-activation of partially-purified inactive renins. Plasma (Step 5) or renal (steps 2 and 4) inactive renin was dialyzed against Buffer G (pH 3.3) for 24 hours at 4 °C . Aliquots were then diluted 30-fold in
Apparent molecular weights by gel filtration were similar to those previously reported* for cruder preparations. Plasma inactive renin was 55,000 and 56,000 daltons in two experiments, and renal inactive renin was 49,000 and 50,500 in two experiments.
Effects of Acidification on Inactive Renin
Both inactive renin preparations were activated during dialysis to pH 3.3. In contrast to trypsinactivated samples, the rate of AI generation by acidactivated inactive renin was nonlinear with time because activation was reversed during 37°C incubation above pH 5. When short incubation times (15 min or less) were used to assay renin activity, the maximal activity produced by acidification was comparable to that produced by trypsin (fig. 4) acidified inactive renin at 37°C in the absence of angiotensinogen caused a time-dependent decrease in activity; activation was completely reversed with the more highly purified renal preparation ( fig. 4 ). Activation was still reversible following combined dialysis to pH 3.3 and pH 7.4, 1 -'* but reversal could be prevented by treating the acidified inactive renin with trypsin. After preincubation of acidified inactive renin for 2 hours at 37°C (pH 8.0), full activity could be restored by trypsin treatment or reacidification (fig. 4) .
Acid Protease Activity in Purified Preparations
Inactive renins from plasma or kidney, both before and after trypsin-or acid-activation, were unable to hydrolyze methemoglobin in the pH 3-5 range. Each preparation solubilized less than 0.1 pmole methemoglobin/hr/ml at pH 3.2, whereas porcine pepsin had an activity of 6800 pmoles/hr//ig under these conditions.
Comparison of Trypsin-Act Ira ted Inactive Renin with Active Renal Renin Reaction with Homologous Angiotensinogen
The rate of AI formation from human angiotensinogen was optimal between pH 5.5 and 6.0 for both sources of activated inactive renin and for active renal renin. Profiles of activity vs pH were virtually identical to those published previously for cruder preparations. ' 1 " All three substances had similar reaction kinetics with human substrate (fig. 5 ). The K m of substrate for active kidney renin ranged from 0.8 to 1. 
Inhibition by Pepstatin
All three substances were inhibited by the acid protease inhibitor pepstatin. The ID M ranged between 3.0 and 4.5 jiM at either 0.4 or 0.8 fiM angiotensinogen. Michaelis-Menten analysis suggested a predominantly noncompetitive or mixed type of inhibition of all three enzymes at low pepstatin concentrations ( fig. 6 ). Values for apparent K, obtained in this way ranged between 2.5 and 3.5 fiM. Higher values were obtained by a Dixon analysis (4.0-5.0
Inhibition by Renin-Specific Antibody
Monospecific antibody to pure human renin inhibited trypsin-activated inactive renins and partiallypurified active renal renin in an identical manner ( fig. 7) . The titer required for 50% inhibition of the activity ranged between 4.5 and 6.0 X 10~8 in four experiments.
Discussion
These studies demonstrate that inactive renin behaves chromatographically as a single substance, distinct from the active form, during extensive purification from both plasma and kidney.f Based on the tin addition to the major peak of renal inactive renin in the nonretained fractions from DEAE-Sepharose ( fig. 2 B) , a minor peak appeared at the beginning of the salt gradient. While this might be taken as evidence of heterogeneity, it is also likely that inactive renin was slightly retarded by the gel and that application of the gradient merely accelerated the elution of the residual bound inactive renin, thereby giving rise to the impression of a second peak. similarity of their binding and elution characteristics in several chromatographic systems, and on the similarity of the activated enzymes in terms of reaction kinetics with homologous substrate and inhibition by pepstatin and antirenin antibodies, it appears likely that the inactive renins derived from plasma and kidney are the same substance.In contrast to active renin, inactive renins from plasma and kidney both bind to affinity gels containing the Cibacron blue ligand and both are unable to bind to pepstatinSepharose in the inactive state. They each exhibit a weaker affinity for anion-exchange resins than the active enzyme. Both renal and plasma inactive renins appear to be glycoproteins, based on their affinity for concanavalin A-Sepharose, and both appear to be strongly hydrophobic.
The present studies also demonstrate that activated plasma and renal inactive renins have catalytic sites that are strikingly similar to that of endogenous renal active renin. Thus, the activated inactive renins and active renal renin had identical pH optimum and reaction kinetics with homologous angiotensinogen, a similar pattern of inhibition by pepstatin, and an identical inhibition profile by antibodies to pure human renin (figs. 5-7). Recent studies have indicated that plasma inactive renin displaces radiolabeled active renin from antiserum to the latter, 1 *' *° suggesting that they share certain immunochemical determinants unrelated to enzymatic activity. Our findings complement these observations since they suggest that activation of purified inactive renin in vitro produces a molecule whose catalytic activity is inhibited identically to that of endogenously-formed active renin by monospecific antibodies. In addition, activated inactive renin and active renin resemble each other in certain chromatographic properties. Activated inactive renin from human amniotic fluid is able, like active renin, to bind to pepstatin-Sepharose." Furthermore, we find that activation eliminates the ability of partially-purified inactive renin to bind to Cibacron blueagarose ( fig. 3 ), confirming earlier observations using crude plasma* 8 or amniotic fluid.* 1 In earlier studies, following small-scale isolation from human kidney9 -w and plasma, 7 '
• inactive renin was found to be completely devoid of enzymatic activity using angiotensinogen as substrate. During the large-scale purification described herein, it was difficult to preserve the plasma and kidney substances in a completely inactive state. It is likely that the "spontaneous" activation that we have observed is due, at least in part, to contaminating proteases. In the initial purification steps from plasma, TAME esterase activity copurified with inactive fenin and may have been responsible for the activation that occurred whenever the serine protease inhibitor benzamidine was removed by dialysis. Since benzamidine is only a competitive inhibitor, it is possible that activation could proceed at a slow rate even in its presence. The present findings suggest, therefore, that there are serine proteases in purified plasma fractions that are able to activate inactive renin without prior exposure to acid pH.
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As previously described in whole plasma," -u both plasma and renal inactive renins could be activated fully by acidification throughout the purification procedures. Therefore, the effects of acidification per se do not appear to depend on the presence of an activating protease. In contrast to trypsin activation, acid activation was reversible during subsequent incubation at higher temperature and pH; however, reversal was complete only with the more highly purified preparation from kidney ( fig. 4) . Previous studies demonstrated that acid activation of inactive renin in whole plasma is not reversible if pH 3.3 dialysis is followed immediately by dialysis to pH 7.4 at low temperature. 18 > "• M This irreversible activation of acidified inactive renin in plasma is mediated by prior activation of the Hageman factor-prekallikrein cascade and proteolytic cleavage of the activated inactive renin by active kallikrein at pH 7.4.
M> " In contrast, we found that acid activation of the more highly purified renal inactive renin is reversible, even if followed by dialysis to pH 7.4 to 4°C; thus it appears that the inability to demonstrate complete reversal in cruder preparations may be due to contaminating proteases that cleave the previously acidified enzyme. Altogether, our data show that the reversible acid activation of plasma and kidney inactive renin is qualitatively similar, thus providing another line of evidence that they are the same substance.
As discussed above, activation of inactive renin in vitro produces a substance that closely resembles active renin in many respects. In addition, activation may reduce the apparent molecular weight to some degree; 9 however, most investigators find that activation does not reduce molecular weight to that of active renin.
•• '• •• w Among the possible explanations for this discrepancy is the likelihood that trypsin treatment or acidification might not mimic the activation that could occur in vivo. In addition, compared to renal renin, larger forms of circulating active renin have been found in human plasma. 9 ' "•" Therefore, it is not clear what the criteria for "conversion" ought to be in terms of molecular size.
In conclusion, our findings suggest that the inactive renin in human kidney is probably the same as that in plasma. This evidence, together with the finding that a similar substance is released by human kidney perfused ex vivo, 16 suggests that the kidney is a source of circulating inactive renin. Finally, it appears that the activated forms of plasma and kidney inactive renin closely resemble partially-purified active renal renin, thus suggesting that inactive renin is either a precursor or a postsynthetic modification of endogenouslyformed active renin. In preliminary studies, we have found that a similar inactive renin was produced by two active renin-secreting neoplasms of nonrenal origin." This evidence of simultaneous production of both active and inactive renin, following neoplastic transformation of cells that normally do not produce renin, raises the possibility that inactive renin is the product of a single gene that also codes for active renin, which would favor the view that inactive renin is a biosynthetic precursor.
